Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413992
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-04-23
Brief Title:
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization Data
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Class:
OTHER
Study ID:
CAFE
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Lead Sponsor Class:
OTHER
Responsible Party:
GUANG WEN YUAN
Responsible Party Title:
Professor MD
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Old Name:
None
Old Organization:
None